• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• BL Club
• Smartbuy
• Books
• Gallery

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Hyderabad, June 23

Pharma major Dr Reddy’s Laboratories Ltd has launched Bispec (Solifencin Succinate) in the domestic market. Used in the management of over active bladder (OAB), Bispec is available in tablet form and in dosages of 5 mg and 10 mg. “Bispec is the best-in-class for OAB and has lesser incidence of dry mouth and constipation. People suffering from OAB have a warning time of about 12 seconds. Solifencin Succinate helps increase the warning time to about 32 seconds,&# 8221; the Hyderabad-based company said in a release. The market size for products used in the treatment of OAB is about Rs 19 crore and is growing at 7 per cent, the release added. The other leading brand of Dr Reddy’s in this segment is TORQ. —

Our Bureau

More Stories on : Announcements | Pharmaceuticals | Dr. Reddy's Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Copyright © 2009, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line